nach oben

Current Bladder Dysfunction Reports

Erschienen in:

28.10.2020 | Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Vaginal Yeast Infection

verfasst von: Mija Blaganje, Matija Barbič

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review includes a detailed overview of the vaginal yeast infection based on current literature available, addressing etiology, epidemiology, risk factors, and pathophysiology, as well as clinical presentation, burden, diagnostic, and treatment strategies.

Recent Findings

There are multiple meta-analyses, systematic reviews, randomized control trials, and critical reviews recently published that have advanced the understanding of pathophysiology and answered questions regarding global burden, prevention, and treatment in a systematic way.

Summary

In the recent years, important work has been made to better understand the pathophysiology and global burden behind the vaginal yeast infection. Diagnostic criteria were proposed for chronic vulvovaginal candidiasis. While fluconazole resistance has been making maintenance suppressive therapy of recurrent vulvovaginal candidiasis difficult and probiotics do not seem to be very effective, significant improvements and advances in the area of antifungal therapeutic innovation research have been made and further results of vaccine trials are pending. There is a need for well-designed RCTs in evidence-based treatment development and research.

Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016;214(1):15–21. https://doi.org/10.1016/j.ajog.2015.06.067.CrossRefPubMed

Reichman O, Margesson LJ, Rasmussen CA, Lev-Sagie A, Sobel JD. Algorithms for managing vulvovaginal symptoms-a practical primer. Curr Infect Dis Rep. 2019;21(10):40. https://doi.org/10.1007/s11908-019-0693-6.CrossRefPubMed

Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369(9577):1961–71. https://doi.org/10.1016/S0140-6736(07)60917-9.CrossRefPubMed

Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016;42(6):905–27. https://doi.org/10.3109/1040841X.2015.1091805.CrossRefPubMed

Petrova MI, Lievens E, Malik S, Imholz N, Lebeer S. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front Physiol. 2015;6:81. https://doi.org/10.3389/fphys.2015.00081.CrossRefPubMedPubMedCentral

Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol Antimicrob. 2020;19(1):5. https://doi.org/10.1186/s12941-020-0347-4.CrossRefPubMedPubMedCentral

• Bradford LL, Ravel J. The vaginal mycobiome: a contemporary perspective on fungi in women’s health and diseases. Virulence. 2017;8(3):342–51. https://doi.org/10.1080/21505594.2016.1237332Enlightens vaginal mycobiome and mechanisms of commensalism and disease.CrossRefPubMed

Landers DV, Wiesenfeld HC, Heine RP, Krohn MA, Hillier SL. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol. 2004;190:1004–10.CrossRef

Drell T, Lillsaar T, Tummeleht L, Simm J, Aaspõllu A, Väin E, et al. Characterization of the vaginal micro-and mycobiome in asymptomatic reproductive-age estonian women. PLoS One. 2013;8(1):e54379. https://doi.org/10.1371/journal.pone.0054379.CrossRefPubMedPubMedCentral

10.

Ene IV, Cheng SC, Netea MG, Brown AJP. Growth of Candida albicans cells on the physiologically relevant carbon source lactate affects their recognition and phagocytosis by immune cells. Infect Immun. 2012;81:238–48. https://doi.org/10.1128/IAI.01092-12.CrossRefPubMed

11.

Niu XX, Li T, Zhang X, Wang SX, Liu ZH. Lactobacillus crispatus modulates vaginal epithelial cell innate response to Candida albicans. Chin Med J. 2017;130(3):273. https://doi.org/10.4103/0366-6999.198927.CrossRefPubMedPubMedCentral

12.

Amjadi F, Salehi E, Mehdizadeh M, Aflatoonian R. Role of the innate immunity in female reproductive tract. Adv Biomed Res. 2014;3:1. https://doi.org/10.4103/2277-9175.124626.CrossRefPubMedPubMedCentral

13.

Pear GT, French AL, Gilbert D, Zariffard MR, Mirmonsef P, Sullivan TH, et al. Human α-amylase present in lower-genital-tract mucosal fluid processes glycogen to support vaginal colonization by Lactobacillus. J Infect Dis. 2014;210(7):1019–28. https://doi.org/10.1093/infdis/jiu231.CrossRef

14.

Blostein F, Levin-Sparenberg E, Wagner J, Foxman B. Recurrent vulvovaginal candidiasis. Ann Epidemiol. 2017;27:575–582.e3.CrossRef

15.

Hong E, Dixit S, Fidel PL, Bradford J, Fischer G. Vulvovaginal candidiasis as a chronic disease: diagnostic criteria and definition. J Low Genit Tract Dis. 2014;18(1):31–8. https://doi.org/10.1097/LGT.0b013e318287aced.CrossRefPubMed

16.

•• Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339–47. https://doi.org/10.1016/S1473-3099(18)30103-8Represents global burden of VYI in numbers.CrossRefPubMed

17.

Donders GGG, Ravel J, Vitali B, Netea MG, Salumets A, Unemo M. Role of molecular biology in diagnosis and characterization of vulvo-vaginitis in clinical practice. Gynecol Obstet Investig. 2017;82(6):607–16. https://doi.org/10.1159/000478982.CrossRef

18.

van der Meijden WI, Boffa MJ, Ter Harmsel WA, et al. 2016 European guideline for the management of vulval conditions. J Eur Acad Dermatol Venereol. 2017;31(6):925–41. https://doi.org/10.1111/jdv.14096.CrossRefPubMed

19.

van Schalkwyk J, Yudin MH. Infectious Disease Committee. Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis. J Obstet Gynaecol Can. 2015;37(3):266–74. https://doi.org/10.1016/S1701-2163(15)30316-9.CrossRefPubMed

20.

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62:e1–e50. https://doi.org/10.1093/cid/civ933.CrossRefPubMed

21.

Owen MK, Clenney TL. Management of vaginitis. Am Fam Physician. 2004;70:2125–32.PubMed

22.

Houang ET, Chappatte O, Byrne D, Macrae PV, Thorpe JE. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother. 1990;34:909–10.CrossRef

23.

Sobel JD, Vazquez JA. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis. 1996;22:726–7.CrossRef

24.

Sobel JD, Kapernick PS, Zervos M, Reed BD, Hooton T, Soper D, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol. 2001;185:363–9.CrossRef

25.

Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178:203–11.CrossRef

26.

Willems HME, Ahmed SS, Liu J, Xu Z, Peters BM. Vulvovaginal candidiasis: a current understanding and burning questions. J. Fungi. 2020;6:27. https://doi.org/10.3390/jof6010027.CrossRef

27.

28.

Collins LM, Moore R, Sobel JD. Prognosis and long-term outcome of women with idiopathic recurrent vulvovaginal candidiasis caused by Candida albicans. J Low Genit Tract Dis. 2020;24:48–52.CrossRef

29.

Sobel JD. Candida vulvovaginitis: treatment – up to date. Wolters Kluwer. https://www.uptodate.com/contents/candida-vulvovaginitis-treatment?search=vulvovaginitois&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3 (Accessed in June 2020; last update, Jun 01, 2020).

30.

• Lírio J, Giraldo PC, Amaral RL, Sarmento ACA, APF C, Gonçalves AK. Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol. BMJ Open. 2019;9(5):e027489. https://doi.org/10.1136/bmjopen-2018-027489Pending to identify the most effective and safe oral and intravaginal antifungal agents.CrossRefPubMedPubMedCentral

31.

•• Zhang Z, Zhang X, Zhou YY, Jiang CM, Jiang HY. The safety of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis. BJOG. 2019;126(13):1546–52. https://doi.org/10.1111/1471-0528.15913In pregnancy oral fluconazole during the first trimester may be associated with heart malformations and spontaneous abortion.CrossRefPubMed

32.

US Food and Drug Administration. Safety communication: Oral fluconazole in pregnancy. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm497656.htm?source=gov delivery&utm_medium=email&utm_source=govdelivery (Accessed in June 2020, released on April 26, 2016).

33.

Sobel JD, Chaim W. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis. 1997;24:649–52.CrossRef

34.

Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol. 2003;189:1297–300.CrossRef

35.

•• Alves IA, Savi FM, de Vasconcelos C, Braz J, Quintans Junior LJ, Serafini MR. The patenting and technological trends in candidiasis treatment: a systematic review (2014–2018). Curr Top Med Chem. 2019;19(28):2629–39. https://doi.org/10.2174/1568026619666191030091211Identified significant improvements and advances in the area of antifungal therapeutic innovation research.CrossRefPubMed

36.

Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG. 2015;122:785–94.CrossRef

37.

•• Edwards JE Jr, Schwartz MM, Schmidt CS, et al. A fungal immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal candidiasis-a phase 2 randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2018;66(12):1928–36. https://doi.org/10.1093/cid/ciy185Therapeutic vaccine could enhance or rectify tolerance/inflammation imbalance in the vagina.CrossRefPubMedPubMedCentral

38.

•• van de Wijgert J, Verwijs MC. Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. BJOG. 2020;127(2):287–99. https://doi.org/10.1111/1471-0528.15870Vaginal probiotics don’t seem to be very effective.CrossRefPubMed

39.

Hillier SL. The need for better evidence to support probiotics for vaginitis. BJOG. 2020;127(2):300. https://doi.org/10.1111/1471-0528.15910.CrossRefPubMed

40.

Ali S, Ashraf U, Shah F, Ali O, Hayes K, Oakeshott P. Re: lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. BJOG. 2020;127(2):304–5. https://doi.org/10.1111/1471-0528.15961.CrossRefPubMed

41.

•• Xie HY, Feng D, Wei DM, et al. Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst Rev. 2017;11(11):CD010496. Published 2017 Nov 23. https://doi.org/10.1002/14651858.CD010496.pub2Vaginal probiotics don’t bring a higher frequency of long-term clinical or mycological cure.

42.

Russo R, Superti F, Karadja E, De Seta F. Randomised clinical trial in women with recurrent Vulvovaginal candidiasis: efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2019;62(4):328–35. https://doi.org/10.1111/myc.12883.CrossRefPubMed

Titel: Vaginal Yeast Infection
verfasst von: Mija Blaganje
Matija Barbič
Publikationsdatum: 28.10.2020
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 4/2020
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-020-00606-z

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Cranberry Products for the Prevention of Catheter-Associated Urinary Tract Infections

Urinary Tract Infection and Pelvic Organ Prolapse—an Association that Needs Further Clarification

Simulation Training in Endo-urology: a New Opportunity for Training in Senegal

Contemporary Landmark Trials Update in the Management of Idiopathic Overactive Bladder